UK Named Patient Supply to GCC
UK Named Patient
Medicines
to GCC Hospitals.
Euro Biom is an MHRA WDA-licensed wholesaler supplying named patient and unlicensed medicines from the UK to hospitals across Saudi Arabia, UAE, Qatar, Kuwait, Bahrain and Oman. SFDA Special Use, MOHAP federal special import, MOPH Qatar, KDFCA, NHRA Bahrain and MoH-DGPA Oman cleared. KFSH, Hamad Medical Corporation and Tawam ready, with ethics-committee-aligned documentation packs.
MHRA WDA Licence No. WDA(H) 59239GCC Named Patient Authorised
⚡ Same-day response to every enquiry · Mon-Fri 09:00-18:00 GMT · WhatsApp us
Why GCC Named Patient Is Different
Five GCC-Specific Failure
Modes on Named Patient Supply.
Modes on Named Patient Supply.
GCC named patient supply is not a regional version of the UK domestic pathway. Post-Brexit MHRA documentation, hospital ethics committee variability across Riyadh, Doha, Abu Dhabi and Kuwait City, regional pricing controls, multi-country shortage rotation and 50 degree summer cold chain all create distinct failure modes that GCC hospital procurement teams must work around.
Post-Brexit MHRA Paperwork
Since 2021 the UK has issued its own Certificate of Pharmaceutical Product, separate from EU CPP. GCC regulators expect specific MHRA fields and signatures. Generic UK suppliers without WDA experience often present incomplete packs that bounce at SFDA or MOHAP review.
Hospital Ethics Committee Variability
KFSH-RC, Hamad and DHCC each run different ethics committee templates for named patient justification. Documentation accepted in Riyadh may need restructuring for Doha. Each hospital handoff demands its own ethics-ready summary, not a generic export pack.
Regional Pricing Controls
Saudi Arabia, UAE and Qatar each maintain reference pricing committees that benchmark named patient and rare disease pricing against EU and UK lists. Without transparent UK source pricing in the documentation pack, named patient applications stall at the price review stage.
Shortage Rotation Across Distributors
When a biologic goes short, GCC distributors quote from rotating UK suppliers, often without verifying MHRA WDA status or stock authenticity. The pack arrives, the hospital pharmacist queries the chain of custody, and the patient supply fails on receipt.
50 degC Summer Cold Chain
Riyadh, Kuwait City and Abu Dhabi summer ambient regularly exceeds 48 degC. Generic packaging qualified for European climates fails on the tarmac. Named patient biologics must ship in climate-specific qualified packaging or arrive temperature-excursed.
The Euro Biom Solution
Named patient supply
built for the GCC
regulator stack.
built for the GCC
regulator stack.
Euro Biom solves GCC named patient at the regulatory architecture level. Every consignment is positioned against the destination country's special use pathway and the receiving hospital's ethics committee template before pack-out. UK source documentation is presented in the format SFDA, MOHAP, DHA, MOPH Qatar, MoH Kuwait or NHRA Bahrain expects on first read, so the special use authorisation does not stall at the regulator desk.
Every shipment leaves under MHRA WDA(H) 59239 with a full GDP documentation pack, calibrated cold chain logger, ethics-committee-ready clinical justification summary and a transparent UK source pricing line. We are recognised by GCC hospital pharmacies and SFDA-registered importers as a credentialled UK source for oncology, rare disease, insulin, autoimmune biologic and paediatric specialty named patient supply.
GCC Regulator Coverage
Saudi Arabia: SFDA Special Use plus MoH Special Cases Committee. UAE: MOHAP federal special import or DHA Dubai and DOH Abu Dhabi special permits. Qatar: MOPH Special Use Committee plus HMC ethics committee. Kuwait: KDFCA special permit plus mandatory local agent. Bahrain: NHRA Special Use Authorisation plus Salmaniya ethics committee. Oman: MoH-DGPA special import plus SQUH academic centre handoff.
MHRA WDA Authorised Six GCC Regulators Covered Ethics Committee Ready Heathrow to GCC Cold Chain
"GCC named patient is not a paperwork problem alone. It is a regulator stack problem. We ship into the segments six GCC regulators recognise on first read, with documentation each hospital ethics committee accepts."
GCC Named Patient Therapeutic Lanes
Four Therapeutic Lanes,
Highest GCC Named Patient Demand.
Highest GCC Named Patient Demand.
GCC hospitals concentrate named patient demand in a defined cluster of therapeutic areas where local registration is absent, slow or commercially unattractive for the marketing authorisation holder. Euro Biom maintains active UK sourcing relationships and ethics-committee-aligned documentation patterns for each.
01
Oncology and Rare Disease Biologics
Therapeutic monoclonal antibodies, CAR-T related ancillaries and novel targeted therapies not yet registered with SFDA, MOHAP or MOPH Qatar. Enzyme replacement therapies for lysosomal storage disorders and mucopolysaccharidoses, with elevated paediatric demand at KFSH-RC and Sidra Medicine. Frozen and 2-8 degC shipping with full ethics committee summary, MA gap rationale and stability file included.
02
Insulins and Diabetes Biologics
Branded insulins, ultra-rapid analogues, GLP-1 receptor agonists and dual agonists not held in routine GCC distributor catalogues. We supply Saudi MoH regional hospitals, MOHAP federal facilities, Hamad Medical Corporation, Kuwait MoH and Salmaniya Medical Complex against named patient and shortage exempt requirements. 2-8 degC validated, with logger trace from Heathrow to consignee.
03
Autoimmune and Specialty Biologics
Immunosuppressants, anti-TNF biologics, IL-17 and IL-23 inhibitors and other autoimmune specialty agents where the destination country MA is pending or not held. Supplied to King Abdulaziz Medical City, Cleveland Clinic Abu Dhabi, Hamad and Sultan Qaboos University Hospital under named patient pathway with full pharmacovigilance handover.
04
Paediatric Specialty and Early Access
Paediatric specialty formulations including specific orphan biologics responding to GCC consanguinity-driven genetic disorder demand at KFSH-RC, Sidra Medicine and SQUH. Post-trial early access programmes for clinical-trial-graduate medicines awaiting commercial registration. HIV post-exposure prophylaxis and rare antivirals for Kuwait Cancer Control Centre and DHCC research facilities.
How We Ship UK to GCC Named Patient
Four stages, one continuous chain
of custody from Heathrow to GCC hospital pharmacy.
Each stage of a GCC-bound named patient shipment is individually controlled and documented. The output is a complete release file alongside the medicine, sufficient for SFDA, MOHAP, DHA, MOPH Qatar, MoH Kuwait or NHRA Bahrain regulator presentation and for the receiving hospital ethics or therapeutics committee.
Stage 01
01
UK MHRA-Authorised Pickup
Product collected from MHRA-authorised UK source under GDP conditions. Pre-conditioned packaging loaded in our qualified cold room. Calibrated logger started before pack seals close.
Stage 02
02
Documentation and Ethics Pack
CPP, batch release, MA verification, GMP certificate, MHRA WDA letter, halal certificate where applicable and ethics-committee-ready clinical summary assembled. Country special use pathway aligned and consignee broker briefed pre-flight.
Stage 03
03
Heathrow to GCC Direct Flight
Direct long-haul flight to RUH, JED, DXB, AUH, DOH, KWI, BAH or MCT on cold-chain-qualified carrier. Tarmac time minimised. Pre-filed customs paperwork accelerates regulator inspection on arrival.
Stage 04
04
Hospital Pharmacy Handoff
Customs cleared under named patient or shortage exempt pathway. Last mile to KFSH, KFMC, Hamad, Sidra, Tawam, Cleveland Clinic Abu Dhabi, KCCC, Salmaniya or SQUH under qualified cold transport. Logger downloaded, release file presented, signature on receipt.
Six GCC Country Routes
One Documentation Spine,
Six Regulator Pathways.
Six Regulator Pathways.
Each GCC state runs its own special use authorisation regime, ethics committee structure and import broker pattern. Euro Biom maintains operational fluency across all six and tunes the documentation pack to the destination route at pack-out.
🇸🇦
Saudi Arabia
SFDA Special Use plus MoH Special Cases Committee
SFDA Special Use authorisation plus Ministry of Health Special Cases Committee for hospital-direct named patient supply. NUPCO 2026 localisation rules explicitly exempt named patient, drug shortage and rare disease enzyme replacement supply, so the UK pathway remains open for these segments. Halal certification included where applicable.
Primary: KFSH-RC Riyadh and Jeddah, KFMC, King Abdulaziz Medical City National Guard
🇦🇪
United Arab Emirates
MOHAP federal plus DHA Dubai and DOH Abu Dhabi
MOHAP federal special import for routine federal facilities, DHA Dubai or DOH Abu Dhabi special permits for emirate-specific hospitals, and a separate clinical research importation route for DHCC free zone facilities. Each pathway demands its own UAE-specific documentation alignment, which Euro Biom assembles at pack-out.
Primary: Tawam Hospital, Sheikh Khalifa Medical City, Cleveland Clinic Abu Dhabi, American Hospital Dubai, DHCC, Mediclinic Middle East
🇶🇦
Qatar
MOPH Special Use Committee plus HMC ethics
MOPH Qatar Special Use Committee approval for named patient and unregistered medicine import, layered with Hamad Medical Corporation ethics committee sign-off for adult cases. Sidra Medicine runs a separate paediatric special-use track aligned to its research and rare disease focus, with documentation tuned to paediatric clinical justification.
Primary: Hamad Medical Corporation, Sidra Medicine
🇰🇼
Kuwait
KDFCA Special Permit plus mandatory local agent
Kuwait Drug and Food Control Authority special permit, with a mandatory local agent which is typically the receiving hospital pharmacy itself. Kuwait Cancer Control Centre is the primary oncology named patient destination, with separate routes for autoimmune biologics and rare disease enzyme replacement therapies through Ministry of Health regional hospitals.
Primary: Kuwait Cancer Control Centre, Ministry of Health regional hospitals
🇧🇭
Bahrain
NHRA Special Use plus Salmaniya ethics
National Health Regulatory Authority Special Use authorisation, paired with Salmaniya Medical Complex ethics committee approval for tertiary care named patient cases. Bahrain volumes are smaller than Saudi or UAE, but per-capita named patient demand is high and turnaround on NHRA approval is faster than the larger GCC neighbours.
Primary: Salmaniya Medical Complex, Bahrain Defence Force Hospital
🇴🇲
Oman
MoH-DGPA Special Import plus SQUH academic
Ministry of Health Directorate General of Pharmaceutical Affairs special import authorisation, with Sultan Qaboos University Hospital as the primary academic centre for named patient and rare disease supply. Oman demand concentrates on paediatric genetic disorders, oncology biologics and rare disease enzymes, served from UK source under cold chain.
Primary: Sultan Qaboos University Hospital, Royal Hospital Muscat
Where GCC Named Patient Demand Concentrates
Eight Therapeutic Areas,
Recognised GCC Named Patient Pull.
Recognised GCC Named Patient Pull.
Named patient demand in the GCC concentrates in a defined cluster of specialty and rare disease therapeutic areas. Euro Biom has supplied across all of the following.
Oncology Biologics
Therapeutic mAbs, targeted therapies, CAR-T related ancillaries for KFSH-RC, KFMC, Hamad, Tawam and Kuwait Cancer Control Centre.
Rare Disease ERT
Enzyme replacement therapies for LSDs and mucopolysaccharidoses. GCC consanguinity rates drive elevated demand, especially paediatric.
Insulin and Diabetes
Branded insulins, ultra-rapid analogues, GLP-1 and dual agonists for the high-prevalence GCC diabetes population, MoH and private hospitals.
Autoimmune Biologics
Anti-TNF, IL-17, IL-23 inhibitors and other autoimmune biologics not registered locally, supplied under named patient with full PV handover.
Paediatric Specialty
Specific orphan biologics and paediatric formulations for genetic disorders at KFSH-RC, Sidra Medicine and Sultan Qaboos University Hospital.
Post-Trial Early Access
Clinical-trial-graduate medicines awaiting commercial registration in the destination country, supplied under named patient or compassionate use.
HIV-PEP and Rare Antivirals
Post-exposure prophylaxis and specialist rare antivirals for tertiary infectious disease centres and DHCC research facilities in the UAE.
Haematology and Other
Clotting factors, recombinant blood factor concentrates, and any other specialty therapeutic area where local registration gaps exist.
GCC Named Patient Documentation Pack
Every GCC consignment
arrives ethics-committee-ready.
arrives ethics-committee-ready.
GCC regulator presentation and the receiving hospital ethics or therapeutics committee handoff each require a defined documentation set. SFDA, MOHAP, DHA, MOPH Qatar, KDFCA, NHRA and MoH-DGPA each look for slightly different fields, but the core pack below is the standard Euro Biom assembles for every GCC named patient consignment, then tuned to the destination country at pack-out.
Submit a GCC Named Patient Enquiry →⚡ Same-day response · WhatsApp us directly
1
UK MHRA Certificate of Pharmaceutical Product
CPP issued by MHRA confirming UK marketing authorisation, product specification and manufacturer credentials. Required by SFDA, MOHAP and MOPH Qatar for special use clearance.
2
Manufacturer Batch Release Certificate
Original batch release from the marketing authorisation holder confirming Quality Control sign-off, batch number, expiry and manufacturing site. Cross-referenced to GCC regulator records where applicable.
3
Marketing Authorisation Verification
UK MA reference, with documented MA gap rationale where the medicine is supplied under named patient pathway against a destination-country prescriber's clinical decision.
4
GMP Certificate for Manufacturing Site
Good Manufacturing Practice certificate for the originating manufacturing site, required by GCC regulators to confirm the source meets recognised pharmaceutical standards.
5
Halal Certificate Where Applicable
Halal certification for products containing animal-derived excipients, required for Saudi Arabia and recommended for UAE, Kuwait and Bahrain hospital pharmacy receipt.
6
MHRA WDA(H) 59239 Holder Letter
Letter on Euro Biom letterhead confirming WDA holder status, GDP compliance and chain-of-custody from MHRA-authorised UK source. Verifiable on the MHRA register.
7
Calibrated Cold Chain Logger Record
Logger trace from pack-out to consignee receipt at hospital pharmacy. Validation against destination-country summer ambient profile included for biologics and vaccines.
8
Ethics Committee Clinical Summary
Written ethics-committee-ready summary aligned to the destination hospital's named patient template. KFSH-RC, Hamad, Sidra and Salmaniya formats supported.
GCC Named Patient Supply, Shipped from London.
Tell us the medicine, the GCC destination and the hospital. We respond the same working day with sourcing options, regulator pathway, ethics-committee-ready documentation outline and pricing. GDP-grade release file included with every consignment.
GCC Named Patient FAQ
UK to GCC Named Patient
Supply, Explained.
Supply, Explained.
Common questions from GCC hospital procurement teams, SFDA-registered importers, MOHAP federal buyers, MOPH Qatar, KDFCA Kuwait, NHRA Bahrain and MoH-DGPA Oman procurement staff sourcing named patient medicines from the UK.
What is named patient medicine supply to the GCC?
Named patient supply is the regulated import pathway for an unlicensed or unregistered medicine, supplied for an identified patient in a GCC hospital where no locally registered alternative is available. Each GCC country runs its own special use authorisation, SFDA Special Use in Saudi Arabia, MOHAP federal special import in UAE, MOPH Special Use Committee in Qatar, KDFCA special permit in Kuwait, NHRA Special Use in Bahrain and MoH-DGPA in Oman. Euro Biom holds MHRA WDA(H) 59239, sources through MHRA-authorised UK channels, and ships under cold chain with ethics-committee-ready documentation.
Which GCC hospitals does Euro Biom supply named patient medicines to?
We supply tertiary referral and specialty hospitals across all six GCC states. Saudi Arabia: King Faisal Specialist Hospital and Research Centre Riyadh and Jeddah, King Fahad Medical City and King Abdulaziz Medical City. UAE: Tawam Hospital, Sheikh Khalifa Medical City, Cleveland Clinic Abu Dhabi, American Hospital Dubai and DHCC clinical research facilities. Qatar: Hamad Medical Corporation and Sidra Medicine. Kuwait: Kuwait Cancer Control Centre. Bahrain: Salmaniya Medical Complex. Oman: Sultan Qaboos University Hospital.
How is GCC named patient supply different from UK domestic named patient?
UK domestic named patient is governed by Regulation 167 of the Human Medicines Regulations 2012 and supplied by an MHRA-licensed wholesaler against a UK prescriber's request. GCC named patient adds three layers, a destination-country regulator special use authorisation, a hospital ethics committee or therapeutics committee approval, and a cold chain plus customs pathway from Heathrow into the destination country. Documentation requirements are heavier and timelines longer. Euro Biom manages the UK end fully and provides documentation packs aligned to each GCC regulator's expectations.
Does NUPCO localisation in Saudi Arabia block named patient imports?
No. NUPCO 2026 localisation rules apply to routine national tenders for products with locally manufactured equivalents. Named patient supply, drug shortage exempt cases, rare disease enzyme replacement therapies and specialty biologics where no local equivalent exists are explicitly exempt. Euro Biom operates exclusively in these exempt segments for Saudi Arabia, supplying SFDA-registered importers and KFSH, KFMC and KFSH-RC under SFDA Special Use authorisation.
What documentation does Euro Biom provide for GCC named patient supply?
Every GCC named patient consignment ships with a UK MHRA Certificate of Pharmaceutical Product, manufacturer batch release certificate, marketing authorisation verification, GMP certificate for the manufacturing site, MHRA WDA holder letter on Euro Biom letterhead, a calibrated cold chain logger record, and a written ethics-committee-ready summary aligned to the destination regulator's special use template. Halal certification is included where applicable for Saudi Arabia and UAE.
How fast can Euro Biom ship a named patient medicine to a GCC hospital?
From order confirmation to consignee receipt at a GCC hospital pharmacy, transit is typically 48 to 72 hours including UK GDP pickup, documentation pack assembly, Heathrow handover, direct flight to the destination, customs clearance and last mile under cold chain. Urgent oncology or rare disease cases can be expedited to 36 to 48 hours where stock is on hand and the destination country special use authorisation is already in place.
What therapeutic areas have the highest named patient demand in the GCC?
Oncology biologics including monoclonal antibodies and CAR-T related ancillaries; rare disease enzyme replacement therapies for lysosomal storage disorders and mucopolysaccharidoses, where GCC consanguinity rates drive elevated paediatric demand; insulins and diabetes biologics for the high-prevalence GCC diabetes population; autoimmune biologics not registered locally; post-trial early access medicines; HIV post-exposure prophylaxis and rare antivirals; and paediatric specialty formulations for genetic disorders. Euro Biom maintains active sourcing relationships across all of these categories.
Related Resources
Further reading for GCC hospital procurement teams, SFDA-registered importers, MOHAP federal buyers and Ministry of Health Special Use Committee staff.
Service
UK Named Patient Medicine Supply, Domestic Hub
View UK service →
Pillar
UK Pharmaceutical Exporter to GCC
View GCC pillar →
Pillar
UK Pharmaceutical Supplier to MENA
View MENA pillar →
Cold Chain
UK Cold Chain Pharma Supply to Saudi Arabia
View Saudi cold chain →
Cold Chain
UK Cold Chain Pharma Supply to UAE
View UAE cold chain →
Vaccines
UK Vaccine Export to Middle East
View vaccine export →
Insulin
UK Insulin Supplier to GCC
View insulin supply →
Country
UK Pharmaceutical Exporter to Saudi Arabia
View Saudi country page →
Country
UK Pharmaceutical Exporter to UAE
View UAE country page →
Country
UK Pharmaceutical Exporter to Qatar
View Qatar country page →
Country
UK Pharmaceutical Exporter to Kuwait
View Kuwait country page →
Country
UK Pharmaceutical Exporter to Bahrain
View Bahrain country page →
Country
UK Pharmaceutical Exporter to Oman
View Oman country page →
Guide
Named Patient Medicines UK: 48-Hour Hospital Sourcing Guide
Read full guide →
Guide
Saudi Vision 2030 NUPCO Localisation Impact
Read NUPCO guide →
Guide
SFDA Drug Registration Guide for UK Exporters
Read SFDA guide →
Guide
MOHAP Import Permits UAE 2026 Guide
Read MOHAP guide →
Guide
Qatar MOPH Pharmaceutical Import Process
Read MOPH guide →
Services
Full Range of Euro Biom Pharmaceutical Services
View services →
Compliance
MHRA WDA Documentation and GDP Standards
View compliance →
Contact
Submit a GCC Named Patient Enquiry
Contact us →